Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 347-355

  Bunnell, Craig A ^a   Supko, Jeffrey G ^b   Eder, Joseph ^a   Clark, Jeffrey W ^b   Lynch, Thomas J ^b   Kufe, Donald W ^a   Shulman, Lawrence N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Chemotherapy; Clinical trials; DX 52 1; Human; Pharmacokinetics; Quinocarmycin

Indexed keywords

7 CYANOQUINOCARCINOL; ANTINEOPLASTIC ANTIBIOTIC; CYTOSTATIC AGENT; QUINOCARMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0034754291     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100319     Document Type: Article

References (28)

1. Analytical and pharmacokinetic studies of a quinocarmycin derivative
2. Antitumor activity of a novel antibiotic, quinocarmycin citrate (KW2152)
3. Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs
4. Computer simulation of the binding of quinocarcin to DNA. Prediction of mode of action and absolute configuration
5. Antitumor activity of quinocarmycin (KW2152) against various cultured leukemia and lymphoma cell lines in vitro
6. Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice
7. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
8. Estimation of variance for harmonic mean half-lives
9. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene
10. Common toxicity criteria
11. Species similarities and differences in pharmacokinetics
12. Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters
13. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2
14. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture and in mice
15. Antitumor antibiotics
16. Synthetic approach to quinocarcin
17. Synthesis and biological evaluation of quinocarcin derivatives
18. Preclinical toxicology studies of quinocarmycin analog DX-52-1
19. Accelerated titration designs for clinical phase I trials in oncology
20. Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection
21. DC-52, a novel antitumor antibiotic. 2. Isolation, physico-chemical characteristics and structure determination
22. Quinocarcin, a novel antitumor antibiotic. 3. Mode of action
23. Solvent and pH-dependent solution equilibration phenomenon of cyanoquinocarcin (DX-52-1) to quinocarcin
24. Synthesis, conformation, crystal structures and DNA cleavage abilities of tetracyclic analogs of quinocarcin
25. 2-dependent cleavage of DNA by quinocarcin
26. Development of a sensitive liquid chromatography-electrospray ionization tandem mass spectrometry method for the measurement of 7-cyanoquinocarcinol in human plasma